Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and risk factors for tuberculosis in HIV-positive subjects by HAART status.
Moreno S, Jarrin I, Iribarren JA, Perez-Elías MJ, Viciana P, Parra-Ruiz J, Gomez-Sirvent JL, Lopez-Aldeguer J, Gutierrez F, Blanco JR, Vidal F, Leal M, Rodríguez Arenas MA, Del Amo J; CoRIS-MD. Moreno S, et al. Int J Tuberc Lung Dis. 2008 Dec;12(12):1393-400. Int J Tuberc Lung Dis. 2008. PMID: 19017448
Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.
del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. del Amo J, et al. Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28. Clin Infect Dis. 2012. PMID: 22460971 Free PMC article.
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D, Imaz A, Perez I, Viciana P, Valencia E, Curto J, Martín T, Castaño M, Rojas J, Espinosa N, Moreno V, Asensi V, Iribarren JA, Clotet B, Force L, Bachiller P, Knobel H, López Bernaldo De Quirós JC, Blanco JR, Rozas N, Vergas J, Ocampo A, Camacho A, Flores J, Gomez-Sirvent JL; KIDAR Study Group. Podzamczer D, et al. J Antimicrob Chemother. 2014 Sep;69(9):2536-40. doi: 10.1093/jac/dku157. Epub 2014 May 15. J Antimicrob Chemother. 2014. PMID: 24833755
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
HIV-CAUSAL Collaboration; Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA. HIV-CAUSAL Collaboration, et al. Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6. Clin Infect Dis. 2015. PMID: 25567330 Free PMC article.
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study.
Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients; Lodwick RK, Sabin CA, Porter K, Ledergerber B, van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A, Jacobson L, De Wit S, Obel N, Castagna A, Wasmuth JC, Gill J, Klein MB, Gange S, Riera M, Mussini C, Gutiérrez F, Touloumi G, Carrieri P, Guest JL, Brockmeyer NH, Phillips AN. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients, et al. Lancet. 2010 Jul 31;376(9738):340-5. doi: 10.1016/S0140-6736(10)60932-4. Epub 2010 Jul 15. Lancet. 2010. PMID: 20638118 Free PMC article.
Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults.
Alvarez M, Monge S, Chueca N, Guillot V, Viciana P, Anta L, Rodriguez C, Gomez-Sirvent JL, Navarro G, de los Santos I, Moreno S, García F; Cohorte de la Red de Investigación en Sida. Alvarez M, et al. Clin Microbiol Infect. 2015 Jan;21(1):104.e1-5. doi: 10.1016/j.cmi.2014.08.005. Epub 2014 Oct 13. Clin Microbiol Infect. 2015. PMID: 25636936 Free article.
The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration. Cain LE, et al. AIDS. 2012 Aug 24;26(13):1691-705. doi: 10.1097/QAD.0b013e328354f497. AIDS. 2012. PMID: 22546987 Free PMC article.
Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.
Podzamczer D, Tiraboschi JM, Mallolas J, Curto J, Cárdenes MA, Casas E, Castro A, Echevarría S, Leal M, Lopez Bernaldo de Quirós JC, Moreno S, Puig T, Ribera E, Villalonga C, Gómez-Sirvent JL, García-Henarejos JA, Lopez-Aldeguer J, Barrufet P, Force L, Santos I, Sanz J. Podzamczer D, et al. Curr HIV Res. 2012 Sep;10(6):513-20. doi: 10.2174/157016212802429820. Curr HIV Res. 2012. PMID: 22716109 Free article.
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
HIV-CAUSAL Collaboration; Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA. HIV-CAUSAL Collaboration, et al. Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001. Ann Intern Med. 2011. PMID: 21502648 Free PMC article.
96 results